Home › Upcoming votes › Entera Bio Ltd.
The deadline as the proxy statement states it: “voting is available until 11:59 p.m. Eastern Time on Monday, November 23, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Entera Bio Ltd.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | APPROVAL OF AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE | Board | For | — |
| 2 | APPROVAL OF A ONE-TIME EQUITY GRANT TO MS. MIRANDA TOLEDANO, OUR CHIEF EXECUTIVE OFFICER AND A DIRECTOR | Board | For | — |
| 3 | APPROVAL OF A ONE-TIME EQUITY GRANT TO MS. DANA YAACOV-GARBELI, OUR CHIEF FINANCIAL OFFICER | Board | For | — |
| 4 | APPROVAL OF A ONE-TIME EQUITY GRANT TO MR. HILLEL GALITZER, OUR CHIEF OPERATING OFFICER | Board | For | — |
| 5 | APPROVAL OF A ONE-TIME EQUITY GRANT TO MR.GREGORY BURSHTEIN, OUR CHIEF OF RESEARCH AND DEVELOPMENT | Board | For | — |
| 6 | APPROVAL OF AN AMENDED AND RESTATED COMPENSATION POLICY | Board | For | — |
| 7 | APPROVAL OF THE AMENDED TERMS OF COMPENSATION OF THE COMPANY'S NON-EXECUTIVE DIRECTORS | Board | For | — |
| 8 | APPROVAL OF EXTENSION OF THE POST-TERMINATION EXERCISE PERIOD FOR OFFICERS AND DIRECTORS | Board | For | — |
From Entera Bio Ltd.’s Form 8-K, filed July 18, 2025, for the meeting held July 16, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| 1. Election of Haya Taitel to the Board of Directors of the Company for a three-year term to hold office until the Company's 2028 Annual Mee | 85% | — |
| 2. Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Company's Definitive Pr | 98% | — |
| 3. Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy Statement, relati | 83% | — |
| 4. Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy Statement, relati | 98% | — |
| 5. Ratification and approval of the Company's amended and restated compensation policy for the directors and officers of the Company, as des | 98% | — |
| 6. Ratification and approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers, as described | 98% | — |
| 7. Ratification and approval o f Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent regist | 99.7% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.